Business
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting, which will be held from April 25-30, 2025, in Chicago, IL. Oral Presentation Details: Title: DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models Presenting author: Paul Novick, Ph.D.Session title: Innovative Approaches in Drug Discovery: Novel Leads, Degraders, and AI-Driven Solutions Session date and time: Monday, April 28, 2025, 2:30 PM – 4:30 PM CST Abstract ID: 3762 Title: Identification of selective, orally bioavailable Aurora A degraders for treatment of pediatric and adult cancers Presenting author: Ryan Rountree, Ph.D.Session title: Degraders and Glues Session date and time: Tuesday, April 29, 2025, 2:30 PM – 4:30 PM CST Abstract ID: 6379 Poster Presentation Details: Title: NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers Presenting authors: Alexandra ‘Sasha’ Borodovsky, Ph.D.Session title: Degraders and Glues 2 Session date and time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CST Abstract ID: 1651 Title: NX-5948 is a CNS-penetrant catalytic Bruton’s tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs Presenting authors: Wylie Palmer, Ph.D.Session title: Targeted Protein Degradation Session date and time: Wednesday, April 30, 2025, 9:00 AM – 12:00 PM CST Abstract ID: 7003 About DEL-AIDEL-AI is Nurix’s discovery platform which employs advanced machine learning to enable all aspects of Nurix’s discovery engine, starting with DNA encoded library (DEL) hit-finding and degrader design, followed by automated chemistry synthesis and direct-to-biology screening and optimization, to rapidly generate degraders and degrader antibody conjugates (DACs) as new chemical entity drug candidates. By leveraging hundreds of billions of DE...